{"organizations": [], "uuid": "8daf9a106d3b5b72161164815e4a28d3a142b702", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-paratek-pharmaceuticals-reports-q1/brief-paratek-pharmaceuticals-reports-q1-loss-per-share-0-91-idUSASC0A0XU", "country": "US", "domain_rank": 408, "title": "Paratek Pharmaceuticals Reports Q1 Loss Per Share $0.91", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-09T19:46:00.000+03:00", "replies_count": 0, "uuid": "8daf9a106d3b5b72161164815e4a28d3a142b702"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-paratek-pharmaceuticals-reports-q1/brief-paratek-pharmaceuticals-reports-q1-loss-per-share-0-91-idUSASC0A0XU", "ord_in_thread": 0, "title": "Paratek Pharmaceuticals Reports Q1 Loss Per Share $0.91", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "paratek pharmaceuticals", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "paratek pharmaceuticals inc", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 9 (Reuters) - Paratek Pharmaceuticals Inc:\n* PARATEK PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS\n* Q1 LOSS PER SHARE $0.91 * Q1 EARNINGS PER SHARE VIEW $-0.91 â€” THOMSON REUTERS I/B/E/S\n* ON TRACK FOR A Q1 2019 OMADACYCLINE U.S. LAUNCH * PREPARING FOR ADVISORY COMMITTEE MEETING, EXPECTED IN LATE SUMMER 2018, TO REVIEW OMADACYCLINE APPLICATIONS\n* PARATEK - AS OF MARCH 31, 2018, HAD CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $184.3 MILLION\n* PARATEK PHARMACEUTICALS - CURRENTLY EXPECTS TO BE ABLE TO FUND OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS THROUGH Q1 2021 (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-09T19:46:00.000+03:00", "crawled": "2018-05-09T15:03:11.006+03:00", "highlightTitle": ""}